Tumor Volumetry (T1 Postcontrast, T2, 18F-FET PET) Response Assessment
| MRI T1 postcontrast (cm3) | MRI T2 (cm3) | 18F-FET PET (cm3) | Response assessment | ||||||||
| Patient no. | Baseline | Follow-up | Change (%) | Baseline | Follow-up | Change (%) | Baseline | Follow-up | Change (%) | RANO* | FET PET† |
| 1 | 68.1 | 29.3 | −57 | 148.8 | 177.4 | 19.2 | 91.0 | 49.9 | −45 | PR | Responder |
| 2 | 7.1 | 45.4 | >1,000 | 97.5 | 110.1 | 13 | 57.5 | 94.3 | 64 | PD | NR |
| 3 | 32.8 | 12.3 | −62 | 218.2 | 135.4 | −38 | 46.9 | 74.6 | 59 | PR‡ | NR‡ |
| 4 | 16 | 11.5 | −28 | 43.3 | 62.6 | 45 | 22.1 | 20.1 | −9 | PD | NR |
| 5 | 12.6 | 3.5 | −72 | 143.0 | 82.9 | −42 | 16.2 | 0.2 | −99 | PR | Responder |
| 6 | 39.7 | 2.5 | −94 | 62.6 | 29.0 | −54 | 67.0 | 5.8 | −91 | PR | Responder |
| 7 | 54.1 | 5.3 | −90 | 180.5 | 154.3 | −15 | 98.3 | 153.8 | 57 | PR‡ | NR‡ |
| 8 | 7.3 | 1.8 | −75 | 151.1 | 168.2 | 11 | 7.0 | 12.8 | 82 | PR‡ | NR‡ |
| 9 | 4.4 | 2.9 | −34 | 107.7 | 133.9 | 24 | 94.2 | 12.9 | −86 | Stable disease | Responder |
| 10 | 11.1 | 10.1 | −9 | 67.6 | 53.4 | −21 | 23.3 | 12.4 | −47 | Stable disease | Responder |
| 11 | 105.6 | 6.8 | −94 | 150.7 | 85.1 | −44 | 104.6 | 90.8 | −13 | PR‡ | NR‡ |
↵* RANO criteria (8): in addition to standard Macdonald criteria, partial response requires stable or improved nonenhancing (T2/FLAIR) lesions; stable disease requires stable nonenhancing lesions; and progressive disease requires a significant increase in nonenhancing lesions.
↵† 18F-FET PET response assessment: responder = uptake reduction ≥ 45%; nonresponder = includes all other situations.
↵‡ Mismatch between RANO (partial responder) and 18F-FET PET (nonresponder) response assessment.
PR = partial response; PD = progressive disease; NR = nonresponder.